Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Melanoma 14Neoplasm Metastasis 5Leukemia, Myeloid, Acute 5Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Uterine Cervical Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Myelodysplastic Syndromes 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Basal Cell 3Burkitt Lymphoma 3Vulvar Neoplasms 2Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Seminoma 2Prostatic Neoplasms 2Penile Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

fludarabine phosphate 2fludarabine 2entinostat 2cabozantinib 2aldesleukin 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Cyclophosphamide 2CTLA-4 Antigen 2oncogene protein E7, Human papillomavirus type 16 1bintrafusp alfa protein, human 1Ritonavir 1Radiotherapy 1Platinum 1Interleukin-2 1Indinavir 1Gemcitabine 1E6 protein, Human papillomavirus type 16 1Cisplatin 1Biopsy 1BAY 1895344 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Penile Neoplasms × CTLA-4 Antigen × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡